<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Middle East Afr J Ophthalmol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Middle East Afr J Ophthalmol</journal-id>
      <journal-id journal-id-type="publisher-id">MEAJO</journal-id>
      <journal-title-group>
        <journal-title>Middle East African Journal of Ophthalmology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0974-9233</issn>
      <issn pub-type="epub">0975-1599</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25949090</article-id>
      <article-id pub-id-type="pmc">4411629</article-id>
      <article-id pub-id-type="publisher-id">MEAJO-22-258</article-id>
      <article-id pub-id-type="doi">10.4103/0974-9233.154411</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Amiodarone-Induced Multiorgan Toxicity with Ocular Findings on Confocal Microscopy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Turk</surname>
            <given-names>Ugur</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Turk</surname>
            <given-names>Bengu Gerceker</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Y&#x131;lmaz</surname>
            <given-names>Suzan Guven</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">2</xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tuncer</surname>
            <given-names>Esref</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alio&#x11F;lu</surname>
            <given-names>Emin</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dereli</surname>
            <given-names>Tugrul</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">Department of Cardiology, Central Hospital, Bayrakli, Izmir, Turkey</aff>
      <aff id="aff2"><label>1</label>Department of Dermatology, Ege University Medical Faculty, Bornova, Izmir, Turkey</aff>
      <aff id="aff3"><label>2</label>Department of Ophthalmology, Ege University Medical Faculty, Bornova, Izmir, Turkey</aff>
      <author-notes>
        <corresp id="cor1"><bold>Corresponding Author:</bold> Dr. Suzan Guven Y&#x131;lmaz, Department of Ophthalmology, Ege University Medical Faculty, TR - 35100 Bornova, Izmir, Turkey. E-mail: <email xlink:href="drsuzan2003@yahoo.com">drsuzan2003@yahoo.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Apr-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>22</volume>
      <issue>2</issue>
      <fpage>258</fpage>
      <lpage>260</lpage>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Middle East African Journal of Ophthalmology</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Amiodarone is an antiarrhythmic medication that can adversely effect various organs including lungs, thyroid gland, liver, eyes, skin, and nerves. The risk of adverse effects increases with high doses and prolonged use. We report a 54-year-old female who presented with multiorgan toxicity after 8 months of low dose (200 mg/day) amiodarone treatment. The findings of confocal microscopy due to amiodarone-induced keratopathy are described. Amiodarone may cause multiorgan toxicity even at lower doses and for shorter treatment periods.</p>
      </abstract>
      <kwd-group>
        <kwd>Amiodarone</kwd>
        <kwd>Confocal Microscopy</kwd>
        <kwd>Multiorgan Toxicity</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-1">
      <title>INTRODUCTION</title>
      <p>Amiodarone is a class III antiarrhythmic agent that is efficacious against all types of tachyarrhythmias. This medication is primarily used for preventing paroxysmal and persistent episodes of atrial fibrillation. However, the duration if use is limited due to the adverse effects association with amiodarone.<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref> In this report, we present a case of persistent atrial fibrillation that developed symptomatic hypothyroidism, skin discoloration, hepatotoxicity and corneal vortex keratopathy after 8 months of amiodarone therapy.</p>
    </sec>
    <sec id="sec1-2">
      <title>CASE REPORT</title>
      <p>54-year-old female was admitted to the outpatient cardiology clinic with paroxysmal palpitation episodes 8 months prior to presentation at our center. Holter-electrocardiogram recordings demonstrated episodes of paroxysmal atrial fibrillation. After comprehensive cardiac evaluation, amiodarone therapy was started at an initial dose of 200 mg/day. General malaise, cold intolerance and blue-gray discoloration of the skin were noticed 7 months later. Dermatologic examination revealed bluish discoloration on the nose and cheeks [<xref ref-type="fig" rid="F1">Figure 1a</xref>]. On histopathology, perivascular brown-gray pigment granule laden histiocytes were observed in the superficial dermis. Laboratory tests indicated slightly elevated serum aminotransferase levels (aspartate aminotransferase 54 &#x3BC;/l [&lt;31], alanine aminotransferase 73 &#x3BC;/l [&lt;34]). Thyroid function tests indicated hypothyroidism (free T4, 0.51 ng/dL [reference range, 0.7&#x2013;2.01]; and thyroid-stimulating hormone, 41.23 &#x3BC;IU/mL [reference range, 0.4&#x2013;3.1]). The patient was referred to an ophthalmologist for potential eye toxicity.</p>
      <p>The patient underwent a complete ophthalmologic examination including measurement of visual acuity (VA), slit-lamp biomicroscopy, applanation tonometry, and dilated fundus examination. VA was 20/20 in both eyes. The intraocular pressures were within normal limits and the fundus examination was unremarkable in both eyes. There was no afferent pupillary defect. Slit-lamp examination indicated vortex keratopathy in both eyes. Vortex keratopathy was classified based on the grading system proposed by Orlando <italic>et al</italic>.<xref rid="ref4" ref-type="bibr">4</xref> The right eye presented with grade 1 vortex keratopathy (characterized by a horizontal line in the inferior third of the cornea), the left eye presented with grade 4 (a whorl-like pattern with additional clumps of pigment) [Figure <xref ref-type="fig" rid="F1">1b</xref> and <xref ref-type="fig" rid="F1">c</xref>]. Both eyes underwent confocal laser-scanning microscopy (CLSM), (Heidelberg Retina Tomograph, HRT II) equipped with the Rostock cornea module (Heidelberg Engineering GmbH, Heidelberg, Germany). CLSM revealed hyper-reflective intracellular inclusions in both corneas. Inclusions were observed in the epithelium, stroma, and subepithelial nerves in both eyes [Figure <xref ref-type="fig" rid="F1">1d</xref>-<xref ref-type="fig" rid="F1">g</xref>]. These findings were more evident in the epithelial basal cell layers. In the left eye with advanced keratopathy (stages 4), bright microdots were also detectable within the posterior stroma. Due to the ocular, skin and thyroid toxicity of the drug, amiodarone therapy was stopped and the patient underwent radiofrequency ablation for atrial fibrillation. Serum aminotransferase levels returned to normal limits after cessation of amiodarone. Although the discoloration of the face and vortex keratopathy regressed, this side effect did not disappear during the 5 months follow-up period.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>(a) Blue-grey discoloration on the nose and central cheeks. Amiodarone-induced corneal opacities; (b) horizontal line in the inferior third of the cornea in the right eye, (c) whorl-like pattern of powdery, white, yellow or brown corneal deposits of the left eye. <italic>In vivo</italic> confocal microscopic images of hyperreflective intracellular inclusions of amiodarone keratopathy (d) in epithelial cells, (e) in basal epithelial cells, (f) in stroma, (g) no deposits in the endothelium</p>
        </caption>
        <graphic xlink:href="MEAJO-22-258-g001"/>
      </fig>
    </sec>
    <sec sec-type="discussion" id="sec1-3">
      <title>DISCUSSION</title>
      <p>Amiodarone is an iodinated benzofuran derivative. It has been associated with toxicity affecting the lungs, thyroid gland, liver, eyes, skin, and nerves. The daily (400 mg/day) and cumulative dose (100 g) combined with the length of therapy is associated with the toxicity. However, toxic effects may also be observed at lower maintenance doses, as observed in our patient.<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref></p>
      <p>The most common cutaneous adverse effect of amiodarone is photosensitivity. Photosensitivity develops in approximately 75% of the patients usually after 4 months of treatment. Photosensitivity may persist between 4 and 12 months after stopping amiodarone. Eight percent of patients can develop hyperpigmentation due to accumulation of amiodarone metabolites on skin exposed to regular sunlight after 20 months of use. The primary step for skin discoloration is cessation of amiodarone. The pigmentation usually resolves within 2 years after cessation of the drug.<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref></p>
      <p>The ocular effect of amiodarone is vortex keratopathy creating a whorl-like pattern by producing lysosomal deposits in the basal epithelial layer.<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref> The whorl-like pattern which was firstly described by Fleischer in 1910 is characterized as powdery, white, yellow, or brown corneal opacities beneath the cornea apex.<xref rid="ref4" ref-type="bibr">4</xref> Amiodarone reaches the cornea via the tear film, aqueous humor, and limbal vasculature. The drug or its metabolites penetrate lysosomes and bind with cellular lipids, producing drug-induced lipidosis.<xref rid="ref7" ref-type="bibr">7</xref> In the eye lysosomal storage leads to typical side-effects. Vortex keratopathy is the most common (70&#x2013;100%) ocular change caused by amiodarone.<xref rid="ref8" ref-type="bibr">8</xref> Although the most common findings are corneal, lens opacities and optic neuropathy have also been reported due to amiodarone.<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref> In the current cases, lens changes and retinal changes were not observed. Photophobia, colored rings around lights and ocular irritation are the common symptoms of patients with amiodarone-induced keratopathy.<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref> However the patient in this case report did not complain of any of these symptoms. Corneal changes secondary to systemic amiodarone can affect all corneal layers.<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref11" ref-type="bibr">11</xref> Our patient also had amiodarone-induced deposits within the corneal epithelium and stroma, but there were no deposits in the endothelial layer. The vision of this patient was not affected. Although corneal deposition is not an indication for drug cessation, patients receiving this medication should be monitored for symptoms related to corneal deposition and ocular toxicity.<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref></p>
      <p>The iodine content of amiodarone effects thyroid functions ranging from mild changes to hypothyroidism or thyrotoxicosis. The frequency of hyperthyroidism and hypothyroidism is 2% and 6% respectively. In case of amiodarone-induced thyroid dysfunction, &#x201C;dronedarone,&#x201D; an iodine free variant of amiodarone is preferred.<xref rid="ref1" ref-type="bibr">1</xref> The patient in this case report complained of general malaise and cold intolerance. These symptoms may be attributed to hypothyroidism. Liver transaminase levels may be elevated in 0.6% of the patients. Amiodarone should be discontinued, if the liver enzymes are three times higher than normal limits.<xref rid="ref1" ref-type="bibr">1</xref> In our patient, liver enzymes were slightly elevated.</p>
    </sec>
    <sec sec-type="conclusion" id="sec1-4">
      <title>CONCLUSION</title>
      <p>This case indicates that multiorgan toxicity due to amiodarone may develop even with short-term use and a low maintenance dose. Hence amiodarone should be used at lowest possible doses. Laboratory studies including liver and thyroid functions should be checked every 6 months and ocular examination should be done regularly to detect ocular side effects to prevent irreversible ocular damages in patients taking amiodarone.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p><bold>Source of Support:</bold> Nil</p>
      </fn>
      <fn fn-type="conflict">
        <p><bold>Conflict of Interest:</bold> None.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siddoway</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Amiodarone: Guidelines for use and monitoring</article-title>
          <source>Am Fam Physician</source>
          <year>2003</year>
          <volume>68</volume>
          <fpage>2189</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="pmid">14677664</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harris</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>McKenna</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Rowland</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Holt</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Storey</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Krikler</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Side effects of long-term amiodarone therapy</article-title>
          <source>Circulation</source>
          <year>1983</year>
          <volume>67</volume>
          <fpage>45</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="pmid">6291807</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rappersberger</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>H&#xF6;nigsmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ortel</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tanew</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Konrad</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wolff</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Photosensitivity and hyperpigmentation in amiodarone-treated patients: Incidence, time course, and recovery</article-title>
          <source>J Invest Dermatol</source>
          <year>1989</year>
          <volume>93</volume>
          <fpage>201</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">2754275</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Orlando</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Dangel</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Schaal</surname>
              <given-names>SF</given-names>
            </name>
          </person-group>
          <article-title>Clinical experience and grading of amiodarone keratopathy</article-title>
          <source>Ophthalmology</source>
          <year>1984</year>
          <volume>91</volume>
          <fpage>1184</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">6514284</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yones</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>O&#x2019;Donoghue</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Menag&#xE9; Hdu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hawk</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Persistent severe amiodarone-induced photosensitivity</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2005</year>
          <volume>30</volume>
          <fpage>500</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="pmid">16045677</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hollander</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Aldave</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced corneal complications</article-title>
          <source>Curr Opin Ophthalmol</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>541</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">15523201</pub-id>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D&#x2019;Amico</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Kenyon</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Ruskin</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
          <article-title>Amiodarone keratopathy: Drug-induced lipid storage disease</article-title>
          <source>Arch Ophthalmol</source>
          <year>1981</year>
          <volume>99</volume>
          <fpage>257</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">6258544</pub-id>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>U&#xE7;akhan</surname>
              <given-names>OO</given-names>
            </name>
            <name>
              <surname>Kanpolat</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ylmaz</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ozkan</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Amiodarone keratopathy: An <italic>in vivo</italic> confocal microscopy study</article-title>
          <year>2005</year>
          <volume>31</volume>
          <fpage>148</fpage>
          <lpage>57</lpage>
        </element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flach</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Dolan</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Sudduth</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Weddell</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Amiodarone-induced lens opacities</article-title>
          <source>Arch Ophthalmol</source>
          <year>1983</year>
          <volume>101</volume>
          <fpage>1554</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">6626008</pub-id>
        </element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gittinger</surname>
              <given-names>JW</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Asdourian</surname>
              <given-names>GK</given-names>
            </name>
          </person-group>
          <article-title>Papillopathy caused by amiodarone</article-title>
          <source>Arch Ophthalmol</source>
          <year>1987</year>
          <volume>105</volume>
          <fpage>349</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="pmid">3827710</pub-id>
        </element-citation>
      </ref>
      <ref id="ref11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>M&#xE4;ntyj&#xE4;rvi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tuppurainen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ik&#xE4;heimo</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Ocular side effects of amiodarone</article-title>
          <source>Surv Ophthalmol</source>
          <year>1998</year>
          <volume>42</volume>
          <fpage>360</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">9493278</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
